Comparison of 5-Fluorouracil and 5-Fluoro-2'-Deoxyuridine as an Effector in Radiation-Activated Prodrugs

References

• Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Nati Cancer Inst 1997; 88: 1210-1215.
   Google Scholar
• Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concur-rent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18: 1458–1464.
   PubMed Web of Science ®Google Scholar
• Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unre-sectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692–2699.
   PubMed Web of Science ®Google Scholar
• Nishimoto S, Haifa H, Ueshima H, Kagiya T. 1-(5'-fluo-ro-6'-hydroxy-5',6'-dihydrouracil 5' yl) 5 fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J Med Chem 1992; 35: 2711-2712.
   Google Scholar
• Shibamoto Y, Thou L, Haifa H, Mori M, Nishimoto S. A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluo-rouracil (OFU001) that release 5-fluorouracil upon hypoxic irradiation. Jpn J Cancer Res 2000; 91: 433–438.
   PubMedGoogle Scholar
• Mori M, Haifa H, Nishimoto S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluo-ro-1-(2'-oxocycloalkyl)uracils as a new class of radiation-acti-vated antitumor prodrugs. J Org Chem 2001; 65: 4641-4647.
   Google Scholar
• Shibamoto Y, Thou L, Haifa H, Mori M, Nishimoto S. In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxo-propyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int J Radiat Oncol Biol Phys 2001; 49: 407–413.
   PubMed Web of Science ®Google Scholar
• Park JG, Collins JM, Gazdar AF, et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Nati Cancer Inst 1988; 80: 1560–1564.
   PubMed Web of Science ®Google Scholar
• Moran RG, Scanlon KL. Schedule-dependent enhance-ment of the cytotoxicity of fluoropyrimidines to human carci-noma cells in the presence of folinic acid. Cancer Res 1991; 51: 4618–4623.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Ohe Y, Nishio K, Ohmori T, Fujiwara Y, Saijo N. In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines. Cancer Chemother Pharmacol 1992; 30: 417–422.
   PubMed Web of Science ®Google Scholar
• Sinnige HA, Timmer-Bosscha H, Peters GF, De Vries EG, Mulder NH. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhi-bition. Anticancer Res 1993; 13: 1335-1340.
   Google Scholar
• Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K. In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neuro-Oncol 1998; 37: 115–121.
   PubMed Web of Science ®Google Scholar
• van Laar JAM, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998; 34: 296–306.
   PubMed Web of Science ®Google Scholar
• Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FMJr. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 1977; 40 (5 Suppl): 2660–2680.
   PubMed Web of Science ®Google Scholar
• Houghton JA, Houghton PJ. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 1980; 45(5 Suppl): 1159–1167.
   PubMed Web of Science ®Google Scholar
• Iigo M, Nishikata K, HoshiA. In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin. Jpn J Cancer Res 1992; 83: 392–396.
   Google Scholar
• Bartkowski R, Berger MR, Aguiar JL. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2'-deoxyuridine (FUDR) and 5-fluo-rouracil (5-FU) in an animal model. J Cancer Res Clin Oncol 1986; 111: 42–46.
   PubMed Web of Science ®Google Scholar
• Naser-Hijazi B, Berger MR, Schmal D, Schlag P, Hull WE. Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy. J Cancer Res Clin Oncol 1991; 117: 295–304.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Nishimoto S, Mi F, Sasai K, Kagiya T, Abe M. Evaluation of various types of new hypoxic cell sensi-tizers using the EMT6 single cell-spheroid-solid tumour system. Int J Radiat Biol 1987; 52: 347–357.
   Web of Science ®Google Scholar
• Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 1986; 77: 908–915.
   PubMedGoogle Scholar
• Matsuoka H, Shibamoto Y, Kubota T, Tsujitani M, Majima T. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas. Oncol Rep 2000; 7: 23–26.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Kubota T, Kishii K, Tsujitani M. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 2000; 56: 265–270.
   PubMed Web of Science ®Google Scholar
• Dennis MF, Stratford MRL, Wardman P, Watts ME. Cellular uptake of misonidazole and analogues with acidic and basic functons. Int J Radiat Biol 1985; 47: 629–643.
   Web of Science ®Google Scholar
• Shibamoto Y, Sasai K, Sakaguchi M, et al. Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use. Int J Radiat Biol 1991; 59: 105–115.
   PubMed Web of Science ®Google Scholar